Vincerx Pharma Inc. has described drug conjugates comprising prodrugs of cyclin-dependent kinase 9 (CDK9) inhibitors covalently linked to an integrin binding moiety through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, cardiac hypertrophy and macular degeneration.
State University of New Jersey (Rutgers) has divulged flavonoids acting as GABA-A receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of alcoholism.
Atsena Therapeutics Inc.’s IND application for ATSN-201 has been cleared by the FDA enabling the company to initiate a phase I/II trial in patients with X-linked retinoschisis (XLRS) caused by pathogenic or likely pathogenic mutations in RS1.
RSS
